New hope for Hard-to-Treat cancers: first human trial of ISM3412 begins
NCT ID NCT06414460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called ISM3412 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and find the best dose. About 80 participants will take part in two stages: first to find a safe dose, then to confirm it works well enough for further testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED / METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
-
Community Cancer Center North
RECRUITINGIndianapolis, Indiana, 46250-2042, United States
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Shanghai Gobroad Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Smilow Cancer Hospital at Yale New Haven Breast Center
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
-
Sun Yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510030, China
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.